AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome

AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome

LONDON and MILAN, Nov. 03, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced the successful closing of a $141 million (€122 million) Series B financing round. The round was co-led by a new lead, Schroders Capital, as well as existing investors Atlas Venture and Forbion. Other new investors included Amgen Ventures, Athos Capit…

AAVantgarde secures $141m Series B funding - European Biotechnology Magazine

AAVantgarde Bio has closed a $141M (€122M) Series B financing round led by Schroders Capital, Atlas Venture, and Forbion. New investors included Amgen Ventures, Athos Capital, CDP Venture Capital, Columbia IMC, Neva SGR, Sixty Degree Capital, XGen Venture, and Willett Advisors. Existing investors Longwood Fund and Sofinnova Partners also participated. AAVantgarde closes $141M Series B to advance Stargardt disease & Usher 1B clinical programmes, …

Amgen Ventures joins $141M Series B for Italian gene therapy biotech AAVantgarde

A Milan-based drugmaker has secured $141 million in a Series B raise backed by Amgen to develop gene therapies for two inherited retinal diseases that cause blindness. AAVantgarde Bio said it will use the funds ...